Grifols, ES0171996087

Grifols strengthens AMBAR evidence: Grifols stock trades at EUR 10.19 before November 10 results

Published on 10/20/2026 at 10:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols cited real-world AMBAR data on September 21, 2026. Grifols stock costs EUR 10.19 on October 20, 2026 before November 10 results.

Operational evidence and reporting date

Grifols strengthened AMBAR evidence with real-world data on September 21, 2026.
Adjusted EBITDA reached EUR 854 million with a 23.9 percent margin in the first half of 2026.
Grifols stock trades at EUR 10.19 at 10:45 a.m. CEST at Lang & Schwarz on October 20, 2026.

Editorialfoto eines Trading-Floors mit Kurscharts und Gesundheitsdaten-Bildschirmen — Börsen-Editorialfoto vom Trading-Floor der Bolsa de Madrid zeigt Charts zu Grifols S.A. ES0171996087 im Gesundheitssektor, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) stock stood at EUR 10.19 at Lang & Schwarz at 10:45 a.m. CEST on October 20, 2026, ahead of the next earnings date of November 10, 2026. On September 21, 2026, Grifols said new real-world evidence strengthened support for its AMBAR program in Alzheimer's disease.

Three milestones shape the story

Grifols reported revenue of EUR 3.574 billion and net profit of EUR 227 million for the first half of 2026. The profit increased 28.7 percent year over year, while revenue grew 2.6 percent at constant currency, according to the company's investor information dated July 28, 2026.

On September 16, 2026, Grifols signed a renewable energy purchase agreement with ENGIE intended to cover more than half of its electricity consumption in Spain. On September 21, 2026, the company reported real-world evidence supporting AMBAR, its Alzheimer's disease program, in the latest media update.

What supports the margin outlook?

The first-half figures point to operating progress alongside the profit increase. Grifols' adjusted EBITDA reached EUR 854 million in the first half of 2026, up 2.4 percent at constant currency, with an adjusted EBITDA margin of 23.9 percent, according to the Yahoo Finance transcript of the July 28, 2026 earnings call. Management also set a full-year 2026 adjusted EBITDA margin target of 25 percent or higher.

November brings the next dates

MarketBeat lists November 3, 2026 for the conference call and November 10, 2026 for the third-quarter 2026 results. Its consensus view points to revenue of USD 2.21 billion and earnings per share of USD 0.3202 for that quarter.

Stock stays tied to execution

The upcoming report will test whether Biopharma growth and the company's margin plans are continuing to offset pressure in other areas. The first-half results provide a concrete baseline, with EUR 91 million of free cash flow before mergers and acquisitions in the first half of 2026.

Grifols stock was trading at EUR 10.19 at Lang & Schwarz on October 20, 2026 at 10:45 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.